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Background: The CCAAT/enhancer binding proteins (C/EBPs) play important roles in carcinogenesis of many
tumors including the lung. Since multiple C/EBPs are expressed in lung, the combinatorial expression of these
C/EBPs on lung carcinogenesis is not known.
Methods: A transgenic mouse line expressing a dominant negative A-C/EBP under the promoter of lung epithelial
Clara cell secretory protein (CCSP) gene in doxycycline dependent fashion was subjected to 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK)-induced lung carcinogenesis bioassay in the presence and absence of doxycycline,
and the effect of abolition of DNA binding activities of C/EBPs on lung carcinogenesis was examined.
Results: A-C/EBP expression was found not to interfere with tumor development; however, it suppressed the
malignant conversion of adenoma to carcinoma during NNK-induced lung carcinogenesis. The results suggested
that Ki67 may be used as a marker for lung carcinomas in mouse.
Conclusions: The DNA binding of C/EBP family members can be used as a potential molecular target for lung
cancer therapy.
Keywords: C/EBPs, Lung chemical carcinogenesis bioassay, Dominant negative, A-C/EBP, Transgenic mouse,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNKBackground
The CCAAT/enhancer binding proteins (C/EBPs) are a
family of basic leucine zipper (B-ZIP) transcription factors
that play important roles in cellular differentiation, proli-
feration, survival, and apoptosis, and metabolism, inflam-
mation, and transformation [1-3]. Six C/EBP family
members have been identified that share the N-terminal
basic amino acid-containing region necessary for DNA
binding and the highly conservative C-terminal leucine
zipper (B-ZIP) dimerization motif [4,5]. Through the B-
ZIP domain, they can homo- and/or hetero-dimerize with
each other to bind specific DNA sequences [4,5].* Correspondence: kimuras@mail.nih.gov
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reproduction in any medium, provided the orAmong the family members, the most studied are C/
EBPα and C/EBPβ. C/EBPα is responsible for blocking
proliferation, promoting differentiation and suppressing
tumorigenesis, thus being considered as a tumor suppres-
sor. Significant down-regulation of C/EBPα expression is
found in cancers of various tissues such as mammary
gland [6], lung [7], and the epidermis [8]. Further, specific
somatic mutations are found in ~10% of acute myeloid
leukemia (AML) patients [9,10]. The reintroduction of C/
EBPα blocked the in vivo tumorigenicity of AML and skin
carcinogenesis [11,12]. In contrast, C/EBPβ is more com-
plex, but has been implicated in playing a role in tumori-
genesis, depending on the cellular context and C/EBPβ
forms present, out of three translational isoforms [3]. In
particular, one of the C/EBPβ isoforms, the C/EBP-liver-
enriched inhibitory protein acts as dominant-negative, and
the increased expression inhibits the transcriptionalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 NNK carcinogenesis bioassay schemes. In Experiment 1,
A-C/EBP+ and – mice were intraperitoneally administered NNK or
PBS at 6 and 7 weeks of age, a half of which were kept under
normal diet while the other half under DOX diet until necropsy that
was carried out at 52 weeks post 1st NNK administration. In
Experiment 2, A-C/EBP+ and – mice were intraperitoneally
administered NNK at 6 and 7 weeks of age. They were maintained
under regular diet for 52 weeks after 1st NNK administration; half
remained under regular diet while the other received DOX diet for
additional 10 weeks. They were subjected to necropsy at 62 weeks
post 1st NNK administration.
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over-expression is found in breast cancers [13,14].
In the lung, three C/EBPs, C/EBPα, C/EBPβ, and C/
EBPδ, are highly expressed with various degrees of expres-
sion depending on protein subtypes, cell types, and/or de-
velopmental stages [15-18]. Similar to tumors of other
organs, C/EBPα is described as a tumor suppressor in lung
cancer [7,19], while C/EBPβ regulates the expression of
Matrix Metalloproteinase (MMP) 1 that mediates extra-
cellular matrix remodeling and promotes tumor invasion
[20]. The role of C/EBPδ in lung carcinogenesis is not
clear. Because of multiple forms of C/EBPs expressed in
the lung, how C/EBPs as a whole contribute to lung car-
cinogenesis is not known.
A-C/EBP is a dominant negative form of C/EBP that
contains leucine zipper dimerization domain and an acidic
region, replacing the basic region of C/EBPs. A-C/EBP
heterodimerizes with all C/EBP family members through
the leucine zipper region of the B-ZIP, and the acidic re-
gion forms coiled coil structure to stabilize the heterodi-
mer, thus blocking the DNA binding of C/EBPs [4]. A
transgenic mouse line (TetO-A-C/EBP) was established
that expresses the A-C/EBP dominant negative gene [4]
under the regulated control of the tetracycline operon
(TetO) promoter [21]. The TetO-A-C/EBP mice were fur-
ther crossed with transgenic mice CCSP-rtTA that express
the rtTA under the promoter of lung epithelial Clara cell-
specific CCSP (SCGB1A1) gene [18]. The progeny of this
cross, named CCSP-rtTA;TetO-A-C/EBP mice were previ-
ously shown to highly express A-C/EBP in the presence of
doxycycline and suppress the transcription of C/EBP-re-
sponsive genes such as secretoglobin 3a2 in lung [18,22].
In this study, CCSP-rtTA;TetO-A-C/EBP mice were sub-
jected to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK)-induced lung carcinogenesis bioassay [23] in the
presence and absence of doxycycline, and the effect of A-
C/EBP expression on the development and/or progression
of lung cancer was examined.
Results
The mean body weights of mice fed Dox-containing diet
when measured at 52 weeks 1st post-NNK administration
were in general larger than those of respective group of
mice fed regular diet in both genotypes (Figure 1, Table 1).
This was particularly evident in NNK-treated group of
mice with statistically significant difference (group 1 vs. 5
and 2 vs. 6, P<0.00001). As expected, the NNK-treated
group of mice developed higher number of alveolar hyper-
plasias, adenomas, and/or adenomas and carcinomas per
mouse with statistical significance as compared to their
respective saline-treated group, regardless of Dox adminis-
tration (Figure 2A, B and Table 1, group 1 vs. 3, 2 vs. 4, 5
vs. 7, and 6 vs. 8). Only a few of them developed carcin-
omas. There was a slight significant increase in theincidence of alveolar hyperplasia with NNK-treated,
regular-diet group of mice as compared with their respec-
tive Dox diet group (group 1 vs. 5). However, no significant
differences were found in the numbers of these lesions
between A-C/EBP+ and A-C/EBP- mice. Only slight
decreases in tumor incidence with almost no statistical sig-
nificance (P=0.0497) was noted in NNK-treated, regular
diet A-C/EBP- mice relative to those of A-C/EBP+ mice
(group 5 vs. 6).
In order to confirm that A-C/EBP was indeed expressed
in A-C/EBP+mice, lung total RNAs were isolated from sev-
eral mice at 52 weeks post-NNK for qRT-PCR analysis. The
A-C/EBP+ mice kept under Dox diet had 2–10 x 106 fold
higher A-C/EBP expression as compared to no expression
of mice with regular diet (data not shown, Ct value 14–17
vs. 34–35, respectively). These results demonstrated that
the expression of A-C/EBP in A-C/EBP+ mice did not have
any effect on NNK-induced lung tumor multiplicity or
incidence.
The effect of A-C/EBP expression on the NNK-induced
adenomas/carcinomas was examined in the second set of
experiment (Figure 1). For this, both A-C/EBP- and A-C/
EBP+ mice were NNK-treated and maintained with a
regular diet for 52 weeks. Thus, they corresponded to
group 5 and 6 mice shown in Table 1, respectively. At
52 weeks post-1st NNK treatment, a half of them started
being fed Dox-containing food, while the other half were
kept under regular diet for additional 10 weeks. They were
subjected to lung necropsy at 62 weeks post-1st NNK ad-
ministration. Similar to the 52 weeks mice, Dox
Table 1 Tumor multiplicities/incidences in NNK or saline-treated A-C/EBP- or A-C/EBP+ mice fed Dox or regular diet and
analyzed at 52 weeks post-NNK/saline administration
Group Genotype
(A-C/EBP





















1 - NNK Dox 45 46.2
±0.8d,e
1.00 0.11g 1.20h 0.044 1.20h 76 (34)c
2 + NNK Dox 30 43.7
±0.8e
1.20 0.23 1.30h 0.13 1.40h 83 (25)
3 - Saline Dox 24 43.7
±1.1
0.29 0.08 0.21 0 0.21 21 (5)
4 + Saline Dox 23 43.4
±0.8f
0.26 0.17 0.17 0 0.17 13 (3)
5 - NNK Regular 44 39.8
±0.8
1.00 0.36 1.30h 0 1.30h 71 (31)i
6 + NNK Regular 40 38.4
±0.9
1.00 0.30 1.50h 0.025 1.60h 88 (35)
7 - Saline Regular 38 40.8
±1.2
0.27 0.18 0.32 0 0.32 26 (10)
8 + Saline Regular 31 39.9
±0.9
0.26 0.19 0.26 0 0.26 19 (6)
aA-C/EBP- is considered as wild-type control.
bPercentage of mice with adenomas or carcinomas.
cNumbers in parentheses show the number of mice having tumors.
dSignificantly different from their respective A-C/EBP+ group (group 1 vs. 2) at P<0.05 by student t-test.
eSignificantly different from their respective regular diet group (group 1 vs. 5, and 2 vs. 6) at P<0.00001 by student t-test.
fSignificantly different from their respective regular diet group (group 4 vs. 8) at P<0.01 by student t-test.
gSignificantly different from their respective regular diet group (group 1 vs. 5) at P<0.05 by student t-test.
hSignificantly different from their respective saline group (group 1 vs. 3, 2 vs. 4, 5 vs. 7, and 6 vs. 8) at P<0.0001 by student t-test.
iSignificantly different from their respective A-C/EBP+ group (group 5 vs. 6) at P=0.0497 by Fisher’s exact test.
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regular diet mice (Table 2, group 1, 2 vs. 3, 4). There were
no differences in the numbers of gross tumors, alveolar
hyperplasias, adenomas, and adenomas and carcinomas
combined between A-C/EBP+ and A-C/EBP- mice with
and without Dox diet. However, interestingly, the carcin-
oma numbers per mouse were significantly lower in A-C/
EBP+ mice as compared with A-C/EBP- mice when they
were fed Dox-containing diet for 10 weeks from 52 weeks
post-1st NNK administration (group 1 vs. 2) as determined
by histopathological analysis. The carcinoma numbers in
A-C/EBP+ mice were also significantly lower as compared
to their respective regular diet group (group 2 vs. 4). In
52 weeks NNK-treated mouse lungs, there were almost no
carcinomas found regardless of genotype or diet (compare
the number of carcinomas between Table 1 and 2), sug-
gesting that the presumable malignant conversion from
adenoma to carcinoma took place between 52 and
62 weeks. In fact, some carcinomas were found inside ad-
enomas, suggestive of this transition (Figure 2C). Malig-
nant tumors were mostly papillary (Figure 2D).
In order to further obtain insight into the malignant con-
version of adenoma to carcinoma, immunohistochemistry
for various markers were carried out using lung sections
prepared at 62 weeks (Table 2). Antibodies used includedthose for vascular endothelial growth factor (VEGF) as a
marker for angiogenesis, Ki67 as a marker for proliferation,
and MMP 2 and 9 that are known to be highly expressed
in cancerous tissues and play a role in their invasion, me-
tastasis and angiogenesis [24,25]. TUNEL assay was also
carried out to detect apoptotic cells. The results demon-
strated that no clear positive staining was obtained for
VEGF and TUNEL in either adenomas or carcinomas,
while MMP 2 and 9 were positive for both adenomas and
carcinomas (data not shown). In contrast, Ki67 was highly
positive for carcinomas, clearly demarcating the adenomas
in the majority of lungs that were histopathologically diag-
nosed as those having carcinomas (Figure 2E, F). Only one
section showed higher positive staining in benign areas
than carcinomas (1 out of 73 lung sections analyzed). To-
gether, these results suggested that A-C/EBP expression in
the presence of Dox may interfere with malignant conver-
sion of adenoma to carcinoma in A-C/EBP+ mice.
Discussion
The current study using transgenic mice expressing do-
minant negative A-C/EBP in lung in Dox-inducible fash-
ion, demonstrated that the expression of A-C/EBP did not
have any effect on the development of lung adenomas in
NNK-induced lung carcinogenesis bioassay. Interestingly,
Figure 2 Representative histology of NNK-induced lung tumors in mice. (A) Alveolar adenoma at low magnification. (B) High magnification
of alveolar adenoma shown in A. (C) Carcinoma (middle and right side) in adenoma (left side of figure). (D) Invasive adenocarcinoma into pleura
and mediastinal fat (invasive front shown by arrows). (E, F) Adenocarcinoma in adenoma for Ki67 staining. Only adenocarcinoma is highly positive
for Ki67. Original magnification: A, 100X, B, C, 400X, D, F, 200X, E, 40X.
Kimura et al. Molecular Cancer 2012, 11:90 Page 4 of 7
http://www.molecular-cancer.com/content/11/1/90however, A-C/EBP expression appeared to have inhibited
the malignant conversion of adenoma to carcinoma in
mice expressing A-C/EBP when the expression was
initiated at 52 weeks post-1st NNK administration, the
time when tumors (mostly adenomas) had already been
well developed (see Table 1), and the mice necropsied at
62 weeks post-1st NNK administration. Malignantprogression of mouse lung adenomas to carcinomas has
been postulated [26,27].
In the current study, the evaluation of malignant pheno-
types was mainly carried out by histopathological analysis.
The diagnosis of the tumors was based on nomenclature
published by the international veterinary pathology com-
mittees [28]. Malignant mouse lung tumors clearly showed
Table 2 Tumor multiplicities/incidences in NNK-treated A-C/EBP- or A-C/EBP+ mice fed Dox or regular diet at 52 weeks




























1 - NNK Dox 19 42.2
±1.4d
2.00 0.37 1.63 0.37e 2.00 95 (17)c
2 + NNK Dox 18 44.5
±1.5d
2.83 0.33 2.06 0.056f 2.11 83 (15)
3 - NNK Regular 18 36.2
±1.6
1.89 0.11 1.50 0.44 1.94 94 (16)
4 + NNK Regular 18 38.1
±1.6
2.22 0.17 2.00 0.44 2.44 78 (14)
aA-C/EBP- is considered as wild-type control.
bPercentage of mice with adenomas or carcinomas.
cNumbers in parentheses show the number of mice having tumors.
dSignificantly different from their respective regular diet group (group 1 vs. 3, 2 vs. 4) at P<0.01 by student t-test.
eSignificantly different from their respective A-C/EBP+ group (group 1 vs. 2) at P<0.05 by student t-test.
fSignificantly different from their respective regular diet group (group 2 vs. 4) at P<0.05 by student t-test.
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lished standards for the diagnosis of malignant lung
tumors of mice using immunohistochemistry, our results
suggest that Ki67 may be used as a marker for carcinomas
in lung carcinogenesis in mice. The correlation of Ki67
with malignant phenotypes has been reported for human
cancers [29-31].
Previously, the effect of A-C/EBP expression on skin
carcinogenesis was examined using K5-tTA;TetO-A-C/
EBP mice, which expressed A-C/EBP in their epidermis
under keratin 5 (K5) promoter in the absence of Dox [21].
When A-C/EBP expression was initiated by giving the
mice regular diet at weaning age, followed by subject to a
skin carcinogenesis assay at 8 weeks of age, they developed
reduced number of squamous papillomas. Further, tumor
regression was observed when K5-tTA;TetO-A-C/EBP
mice were first allowed to develop skin papillomas in the
presence of Dox, and then Dox was withdrawn from the
diet [21]. Most papillomas regressed within 4 weeks of the
start of Dox diet. Thus the effect of A-C/EBP on skin pa-
pilloma development appeared different from that of
NNK-induced lung carcinogenesis found in this study.
The phenomenon found in the skin carcinogenesis study
was due to A-C/EBP-induced expression of p53 and apop-
tosis, partially acting through C/EBPβ [21].
Lung expresses three C/EBPs, C/EBPα, C/EBPβ, and C/
EBPδ at various degrees depending on protein subtypes,
cell types, and/or developmental stages [15-18]. How these
multiple C/EBPs interact and/or interfere with each other
to regulate downstream genes, particularly those involved
in carcinogenesis is not known. C/EBPα is well established
as a tumor suppressor in many tumors including lung
[7,19], while C/EBPβ is suggested to be involved in lung
tumorigenesis [3,13,14]. Although the role of C/EBPδ in
lung carcinogenesis has not been known, it is generallyconsidered as tumor suppressor. However, it may also play
a role in tumor progression and metastasis [32,33]. Based
on the opposite and/or dual roles that each C/EBP plays,
lung carcinogenesis may be influenced by a slight drift
from the delicate balance built among activities of these
C/EBPs. It is possible that the expression of A-C/EBP
might affect malignant conversion of lung tumors through
C/EBPβ and/or C/EBP δ. The precise mechanism for the
effect of A-C/EBP on NNK-induced lung carcinogenesis,
and how that explains the difference between the previous
skin carcinogenesis and the current lung carcinogenesis
studies require further experiments.
In the current carcinogenesis study, we found that Dox
did not have any effect on NNK-induced lung carcinoge-
nesis, even though Dox was demonstrated to inhibit
tumor growth and tumor-associated vascular hyperperme-
ability [34]. Only difference found in the current study
was that Dox-treated groups of mice had slight weight
gain as compared to regular diet groups. We do not know
the reasons for this phenomenon.
In our previous study, the expression levels of A-C/EBP
in A-C/EBP+ mice were already elevated approximately 3
fold after 3 days of Dox exposure, which were further
increased to 10 fold in lungs of 4 months-old A-C/EBP+
mice as compared to A-C/EBP- control mice [22]. In the
current study, A-C/EBP+ mice maintained under Dox feed
for more than a year exhibited 2–10 × 106 fold higher A-
C/EBP expression as compared to no expression of mice
with regular diet. These results demonstrated that A-C/
EBP+ mice indeed expressed A-C/EBP throughout their
lives under Dox feed, and the expression level appeared
kept increasing. With this level of A-C/EBP, it can be said
that all DNA binding activities of C/EBPs were likely to be
totally abolished during the entire period of carcinogenesis
study.
Kimura et al. Molecular Cancer 2012, 11:90 Page 6 of 7
http://www.molecular-cancer.com/content/11/1/90Conclusions
The total abolition of DNA binding activity of C/EBPs
through A-C/EBP expression may not contribute to the de-
velopment of adenomas, but may play a role in the malig-
nant conversion from adenomas to carcinomas during
NNK-induced lung carcinogenesis in mice. The results im-
plicate that the DNA binding of C/EBP family members
can be used as a potential molecular target for the therapy
of lung cancers. The results further suggest that Ki67 may
be used as a marker for lung carcinogenesis in mice.
Methods
Animals and chemicals
The mice used in this study were CCSP-rtTA;TetO-A-C/
EBP and CCSP-rtTA mice. The details for characterization
and genotyping were previously described [18,22]. Mice
carrying A-C/EBP gene (CCSP-rtTA;TetO-A-C/EBP) were
tentatively termed A-C/EBP+ while mice not carrying A-
C/EBP gene (CCSP-rtTA) were termed A-C/EBP-. The A-
C/EBP+ mice expressed A-C/EBP in the presence of
doxycycline while the A-C/EBP- mice did not. The latter
was considered as the wild-type control. 4-(Methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK) was purchased
from Toronto Research Chemicals, Inc. (North York,
Ontario, Canada). Mice for these experiments were bred
in our animal facility.
Animal treatment
Male mice were used for all experiments. For the 1st set of
experiment, A-C/EBP+ and A-C/EBP- mice were intraper-
itoneally injected with NNK (dissolved in saline, 103 mg/
kg per injection) or saline as control at 6 and 7 weeks of
age (Figure 1). A half of the NNK or control group of mice
were fed food containing 200 mg/kg doxycycline (Dox),
and the other half fed control diet from birth continuously
until necropsy, at 52 weeks post-1st NNK administration.
For the 2nd experiment, all mice were injected with NNK
as described above and were maintained under normal
feed for 52 weeks. At 52 weeks post-1st NNK treatment,
half of them were fed Dox-containing food while the
others stayed with the regular diet for an additional
10 weeks. They were killed at 62 weeks post-1st NNK ad-
ministration. All experiments were conducted in accor-
dance with the National Institutes of Health guidelines
after approval by the National Cancer Institute (NCI) Ani-
mal Care and Use Committee.
Lung tumor analysis
Gross number of lung tumors was counted at the time of
necropsy. Lungs were fixed in 10% neutral buffered forma-
lin, embedded in paraffin, sectioned at 5 μm thickness,
and stained with hematoxylin and eosin for histological
examination. The number of lung nodules was counted
grossly and histologically, and the number of alveolarhyperplasias, adenomas, and carcinomas were recorded
per mouse using a whole lung section [28,35]. The statis-
tical analysis was carried out using student t-test for tumor
multiplicity and Fisher’s exact test for tumor incidence.
P<0.05 was considered as statistical significant.
Immunohistochemistry
Immunohistochemical staining was carried out by the
avidin-biotin-peroxidase complex method (Vector Labora-
tories, Burlingame, CA) using rabbit anti-Ki67 antibody
(1:500, Abcam, Cambridge, MA). Immunostaining was
visualized using 3, 3’-diaminobenzidine (DAB) as substrate
(DAKO, Carpinteria, CA) and counterstained with
hematoxylin (Sigma-Aldrich, St Louis, MO).
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was isolated from lung using the TRIzol reagent
(Invitrogen, Life Technologies, Carlsbad, CA). Complemen-
tary DNA (cDNA) was synthesized from 2 μg of RNA using
the Superscript III reverse transcriptase (Invitrogen). qRT-
PCR was performed with the cDNA using the following-
specific primers: 5’-CCA CGC TGT TTT GAC CTC CAT
AG-3’ and 5’-ATT CCA CCA CTG CTC CCA TTC-3’ for
A-C/EBP and 5’-ATG GAG GGG AAT ACA GCC C-3’
and 5’-TTCTTTGCAGCTCCTTCGTT-3’ for β-actin as
normalization control. The qRT-PCR condition used was
as follows: denaturation at 95°C for 15 sec, annealing at 60°
C for 15 sec, and extension at 72°C for 30 sec for 40 cycles.
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